Published in Oncotarget on January 01, 2012
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol (2012) 1.30
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol (2013) 1.05
Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) (2013) 1.00
Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival. Oncotarget (2013) 0.99
Stem cell niches in glioblastoma: a neuropathological view. Biomed Res Int (2014) 0.96
CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment. Front Cell Neurosci (2014) 0.96
COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget (2014) 0.93
Growth arrest and forced differentiation of human primary glioblastoma multiforme by a novel small molecule. Sci Rep (2014) 0.91
Automated discrimination of lower and higher grade gliomas based on histopathological image analysis. J Pathol Inform (2015) 0.89
Glioma Stem Cells: Signaling, Microenvironment, and Therapy. Stem Cells Int (2016) 0.88
Glioma Stem Cells and Their Microenvironments: Providers of Challenging Therapeutic Targets. Stem Cells Int (2016) 0.85
New perspectives in glioblastoma antiangiogenic therapy. Contemp Oncol (Pozn) (2015) 0.78
Glioblastoma: Defining Tumor Niches. Trends Cancer (2015) 0.78
Registered report: tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Elife (2015) 0.77
DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma. Oncotarget (2016) 0.75
Glioblastoma Stem-Like Cells: Characteristics, Microenvironment, and Therapy. Front Pharmacol (2016) 0.75
Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma. Oncotarget (2016) 0.75
Molecular pathways: not a simple tube--the many functions of blood vessels. Clin Cancer Res (2014) 0.75
Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell (2016) 0.75
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol (2016) 0.75
Malignant pericytes expressing GT198 give rise to tumor cells through angiogenesis. Oncotarget (2017) 0.75
3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy. Cancer Res (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of human brain tumour initiating cells. Nature (2004) 38.87
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol (2007) 12.62
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med (2001) 9.53
Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science (2004) 9.10
Genetic pathways to glioblastoma: a population-based study. Cancer Res (2004) 8.87
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell (2008) 8.01
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol (2009) 7.73
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol (1999) 7.66
Isolation of a tumor factor responsible for angiogenesis. J Exp Med (1971) 7.12
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell (2011) 6.43
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol (2005) 6.16
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature (2010) 6.13
Brain tumour stem cells. Nat Rev Cancer (2006) 5.84
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer (2007) 4.54
Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med (2004) 3.63
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain (2010) 3.53
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45
Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol (2009) 3.38
Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell (2010) 3.34
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res (2004) 2.78
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol (2009) 2.77
Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature (2004) 2.54
Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol (2005) 2.16
The brain tumor microenvironment. Glia (2011) 2.13
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget (2010) 1.92
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol (2010) 1.86
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev (2010) 1.82
Vasculogenic mimicry. APMIS (2004) 1.76
Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer (2002) 1.69
Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol (2007) 1.62
Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol (2004) 1.61
Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol (2009) 1.51
Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest (2001) 1.50
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res (2003) 1.50
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol (1997) 1.37
Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem (2005) 1.37
Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res (2003) 1.35
The perivascular niche microenvironment in brain tumor progression. Cell Cycle (2010) 1.30
Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cell Mol Med (2009) 1.30
p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene (2000) 1.20
Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol (2001) 1.19
Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer (2008) 1.08
Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget (2010) 1.05
Incorporation of bone marrow-derived Flk-1-expressing CD34+ cells in the endothelium of tumor vessels in the mouse brain. Neurosurgery (2006) 1.05
Smooth muscle can comprise the sarcomatous component of gliosarcomas. J Neuropathol Exp Neurol (1992) 1.00
Tumor sinuses- vascular channels. Pathol Oncol Res (2000) 0.97
Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors. Oncotarget (2010) 0.96
Gliomyosarcoma. Report of a case of rhabdomyosarcoma arising in a malignant glioma. Acta Neuropathol (1986) 0.95
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma. Aging (Albany NY) (2010) 0.89
Gliosarcoma with features of chondroblastic osteosarcoma. Cancer (1993) 0.85
Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature. Acta Neuropathol (2003) 0.83
Gliosarcoma with cartilage formation. Cancer (1989) 0.79
A conspiracy of glioma and endothelial cells to invade the normal brain. Oncotarget (2011) 0.79
Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res (2010) 0.79
Gliosarcoma with liposarcomatous differentiation: the new member of the lipid-containing brain tumors family. Arch Pathol Lab Med (2006) 0.78
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
p16INK4a induces an age-dependent decline in islet regenerative potential. Nature (2006) 9.09
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol (2010) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Medulloblastoma growth inhibition by hedgehog pathway blockade. Science (2002) 6.53
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell (2008) 4.68
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet (2009) 4.52
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res (2006) 3.81
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res (2006) 3.72
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells (2007) 3.47
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells (2010) 3.42
FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell (2009) 3.37
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res (2006) 3.06
Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature (2012) 2.96
Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 2.90
Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron (2012) 2.84
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
The neurobiology of autism. Brain Pathol (2007) 2.63
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol (2008) 2.40
Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell (2002) 2.37
Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med (2013) 2.31
Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci (2007) 2.31
Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell (2009) 2.18
The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev (2005) 2.14
BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One (2011) 2.04
Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol (2011) 2.01
Human glioma growth is controlled by microRNA-10b. Cancer Res (2011) 1.96
Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A (2013) 1.95
Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol (2007) 1.92
The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell (2011) 1.92
Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol (2008) 1.87
Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol (2010) 1.86
The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res (2008) 1.84
Abnormal expression of REST/NRSF and Myc in neural stem/progenitor cells causes cerebellar tumors by blocking neuronal differentiation. Mol Cell Biol (2006) 1.83
A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol Ther (2011) 1.76
Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A (2004) 1.76
Genomic amplification of orthodenticle homologue 2 in medulloblastomas. Cancer Res (2005) 1.75
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A (2011) 1.75
Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res (2011) 1.71
Medulloblastoma stem cells. J Clin Oncol (2008) 1.71
Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res (2009) 1.66
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res (2006) 1.66
Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol (2007) 1.64
DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet (2013) 1.64
A mouse model of blast injury to brain: initial pathological, neuropathological, and behavioral characterization. J Neuropathol Exp Neurol (2011) 1.62
BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. Clin Cancer Res (2011) 1.61
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Establishment and characterization of a primary human chordoma xenograft model. J Neurosurg (2012) 1.60
The Notch target Hes1 directly modulates Gli1 expression and Hedgehog signaling: a potential mechanism of therapeutic resistance. Clin Cancer Res (2010) 1.58
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol (2011) 1.53
Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res (2009) 1.52
Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res (2008) 1.51
Unfolded protein response in fuchs endothelial corneal dystrophy: a unifying pathogenic pathway? Am J Ophthalmol (2010) 1.49
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Three-dimensional amide proton transfer MR imaging of gliomas: Initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging (2013) 1.43
Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem Int Ed Engl (2010) 1.43
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev (2008) 1.42
Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res (2005) 1.40
A clinicopathologic series of primary graft failure after Descemet's stripping and automated endothelial keratoplasty. Ophthalmology (2008) 1.40
Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids (2013) 1.38
Iris cross-sectional area decreases with pupil dilation and its dynamic behavior is a risk factor in angle closure. J Glaucoma (2009) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol (2005) 1.34
Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Res (2013) 1.33
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol (2012) 1.33
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res (2007) 1.32
Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res (2013) 1.31
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget (2013) 1.28
Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition. Cancer Lett (2012) 1.26
Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proc Natl Acad Sci U S A (2010) 1.25
Spectrum of pilomyxoid astrocytomas: intermediate pilomyxoid tumors. Am J Surg Pathol (2010) 1.23
Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS One (2012) 1.23
Embryonal tumors with abundant neuropil and true rosettes: a distinctive CNS primitive neuroectodermal tumor. Am J Surg Pathol (2009) 1.23
Hedgehog signaling promotes medulloblastoma survival via Bc/II. Am J Pathol (2007) 1.22
Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A (2010) 1.21